Spanish CDMO working ahead of EU serialisation deadline6 Dec 2018
Company now able to serialise commercial batches manufactured by them for clients; it can also offer standalone serialisation services as an outsourcing partner.
CDMO Idifarma has confirmed it is ready to meet forthcoming EU serialisation regulations.
Following a €200k investment, the Antares Vision Print&Check EVO-TE carton serialisation station is now installed and fully operational at Idifarma’s EU-GMP approved plant in Pamplona, Spain.
The announcement comes ahead of the EU Falsified Medicines Directive’s (EU FMD) February 2019 deadline for the serialisation of licensed drug products.
Luis Oquiñena, general manager and co-founder of Idifarma said: “Supporting our customers to meet new regulatory requirements and combat counterfeit medicines is very important to us.
“We have worked closely with our customers, the manufacturers of this machine and track and trace software vendors like TraceLink to ensure that our capabilities meet both existing and potential new clients’ needs.
“This machine offers us the flexibility to upgrade for future regulatory or client requirements and will enable us to help protect our clients’ products and the public against counterfeit pharmaceuticals.”
The industry-wide EU FMD regulation is a legal requirement for all pharmaceutical companies intended to improve traceability of drugs, help in the fight against counterfeit products entering the supply chain and ultimately improve patient safety.Oquiñena added: “Our investment offers real support to our clients as they too prepare to meet the regulations. Not only can we serialise commercial batches manufactured by Idifarma for clients, but we can also offer standalone serialisation services as an outsourcing partner.
“As the deadline draws closer, we are seeing heightened interest for these specialised outsourced services and fully expect to see demand increase even further in early 2019.”
The investment in serialisation follows the expansion of both its spray drying and capsule filling capabilities and strengthens Idifarma’s position as a specialised contract partner for the development and manufacturing of oral solid dosage forms, including high potency compounds, and niche pharmaceuticals requiring small batches.
WuXi AppTec expands site in California for pharmaceutical R&D services
13 Dec 2018
Expanded facility will establish a center of excellence in screening, discovery biology, pharmacology, and small molecule process R&D including Phase I GMP manufacturing.Read more
Cambrex expands analytical capabilities
12 Dec 2018
The $1 million investment will assist in getting new products to commercial launch faster.Read more
MIT engineers repurpose wasp venom as an antibiotic drug
9 Dec 2018
Altered peptides from a South American wasp’s venom can kill bacteria but are nontoxic to human cells.Read more
Fluidic Analytics raises $31m to launch new lab tools and unlock biology behind major diseases
5 Dec 2018
The financing will power the global commercial launch of the company's Fluidity One system.Read more
OnDosis and Recipharm partner to advance a novel treatment regimen for ADHD
4 Dec 2018
The new treatment will leverage OnDosis’ proprietary technology, which integrates oral drugs in form of micro units and individualised dosing, in a handheld device.Read more
NIH to evaluate effectiveness of male contraceptive skin gel
28 Nov 2018
The gel formulation includes the progestin compound segesterone acetate, in combination with testosterone, and is applied to the back and shoulders and absorbed through the skin.Read more
QPS expands US-based Phase I clinical trial capabilities
27 Nov 2018
Expansion supports the growing needs of the company's pharmaceutical, biotechnology and CRO partners.Read more
Grant winners to investigate continuous manufacturing for gene therapies
26 Nov 2018
Cobra Biologics, Pall, and the Cell and Gene Therapy Catapult share £1.5 million grant from the UK's innovation agency.Read more
Proprietary nasal delivery formulation of diazepam reaches NDA
7 Nov 2018
The absolute bioavailability of the Valtoco intranasal formulation was 96% of intravenous diazepam in a Phase I cross-over trial.Read more
Plasticell receives EU funding to advance neurodegenerative disease research
1 Nov 2018
Th company's CombiCult combinatorial cell culture technology will be used to generate high fidelity, progenitor and terminally differentiated neuronal and glial cell subtypes for incorporation into next-generation models.Read more
Are you a supplier
Here's what we can do for you
- Generate quality leads for your business
- Stay visible for 365 days of the year
- Receive product inquiries and respond to meeting requests directly
- Improve company online presence through Search Engine Optimisation